PACS Group COO Jergensen Executes Largest 10b5‑1 Sale of 2026—Insider Trading Signals Confidence, Not Panic

Insider Selling on a High‑Growth Healthcare Stock The latest Form 4 from PACS Group Inc. shows President & COO Jergensen Joshua selling 36,502 shares on 16 September 2026 as part of a Rule 10b5‑1 trading plan. The transaction, priced at a weighted average of $43.08, reduces his stake to 2,499,818 shares—about 0.38 % of outstanding shares. While the sale is modest relative to the company’s $6.66 billion market cap, it follows a pattern of regular divestitures that have been occurring for the past several months.

What the Pattern Says About Investor Sentiment Joshua’s insider activity has been highly consistent: from early March 2026, he has sold roughly 30–40 k shares per month, occasionally offset by larger sales in July and September. The most recent block is the largest since the March 24 buy of 146,498 shares. These moves occur at a time when the stock has already fallen 6.2 % in one week, 4 % in the month, and the underlying fundamentals remain solid—PACS’s revenue growth has surged 251 % year‑to‑year, and its P/E sits near 25, well below the sector average. The timing suggests Joshua is using his predetermined trading plan rather than reacting to short‑term price swings, which investors often interpret as a signal of confidence in the long‑term business model.

Implications for the Company and Its Shareholders The cumulative effect of Joshua’s sales is a gradual dilution of his personal holdings, but it does not materially impact the overall ownership structure. The company’s capital structure remains stable, and the recent insider selling has not triggered any regulatory red flag. For investors, the key takeaway is that insider plans are now fully in motion, and if the company continues to post strong earnings and expand its product pipeline in health‑care imaging, the stock could rebound. Conversely, if the company encounters regulatory delays or competitive pressure, the planned sales may accelerate, creating downward pressure on price.

Who Is Jergensen Joshua? A Brief Profile Joshua has been with PACS Group since 2024 and rose quickly to President & COO. His insider trade history shows a disciplined, rule‑based approach: most sales are executed under a 10b5‑1 plan adopted in March 2026, with weekly blocks ranging from 3,500 to 36,500 shares. He also occasionally buys shares—most notably in March 2026 and December 2025—suggesting a long‑term ownership conviction. Compared to peers, Joshua’s selling frequency is moderate; he is neither a “hot‑hand” trader nor a passive holder. This balance indicates a focus on liquidity and personal financial planning rather than speculation.

Takeaway for Investors Insider selling is normal, and Joshua’s recent activity fits within an established plan. The stock’s recent decline may represent a buying opportunity for those who believe PACS’s fundamentals will drive a recovery. Investors should monitor upcoming earnings, regulatory filings, and any further insider moves—particularly from other directors such as Mark Hancock—before making a decision.